Program

The future of prostate cancer screening programme in EU: Evidence, technologies and strategies

ESUI Plenary session 1

Location              Callelongue

Chairs   Urologist – L. Budäus,Hamburg (DE)

09:10 – 09:30    EU recommendations on PCa screening programme: What we expect in the next 5 years

Urologist – H. Van Poppel,Leuven (BE)

09:30 – 09:50    Strategies to screen population

09:30 – 09:40    Challenges of MRI in (any) screening programmes

Radiologist – I.G. Schoots,Rotterdam (NL)

09:40 – 09:50    The lung cancer screening model

T.G. Blum,Berlin (DE)

09:50 – 10:10    Prostate cancer screening: The PSA/biomarker implemented pathway 10:00 – 10:10        ProSa

Radiologist – V. Panebianco,Rome (IT)

10:10 – 10:30    Prostate cancer screening: The MRI only pathway

10:10 – 10:20    Prostagram Trial

D. Eldred-Evans,London (GB)

10:20 – 10:30    Re-Imagine Trial

S. Punwani,London (GB)

10:30 – 10:50    Q&A and discussion

Other imaging modalities – updates for PCa diagnostic

ESUI Plenary session 2

Location Callelongue

Chairs M. Mischi,Eindhoven (NL)

Urologist – V. Scattoni,Milan (IT)

11:10 – 11:20 Ultrasound based – mpUS trial

Urologist – T. Loch,Flensburg (DE)

11:20 – 11:30 PSMA based (DEPROMP trial)

Urologist – M. Ritter, Bonn (DE)

11:30 – 11:40 Arti¦cial Intelligence/MRI based: The ProCancer-I project

J. Almeida,Lisbon (PT)

11:40 – 11:50 Machine Learning/3D-US based: PCaVision trial

H. Wijkstra,Amsterdam (NL)

Latest evidence in imaging trials and their clinical implications

ESUI Plenary session 3

Location              Callelongue

Chairs   Urologist – V. Kasivisvanathan,London (GB)

11:50 – 12:00    ZIRCON – Girentuximab-PET/CT in RCC phase III trial

Case presenter  Urologist – P. Mulders,Nijmegen (NL)

12:00 – 12:03    Discussion

12:03 – 12:13    PRIME – BiParametric MRI phase III trial

Case presenter  Urologist – V. Kasivisvanathan,London (GB)

12:13 – 12:16    Discussion

12:16 – 12:26    PRECISE trial: MRI features predicting active surveillance failure

Case presenter  Urologist – A. Stabile,Milan (IT)

12:26 – 12:29    Discussion

12:29 – 12:30    Conclusion

Abstract session

ESUI Abstract Session

Location              Callelongue

Chairs   Urologist – P. Martino,Bari (IT)

O01       MRI in penile cancer: Correlating examination and histopathology with imaging

Urologist – M. Gupta,Bangalore (IN)

O02       Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on PSMA-PET: Results of a Multicenter, European Study

Urologist – P. Rajwa,Zabrze (PL)

O03       Complete biochemical response below 0.1 ng/ml predicts long-term therapy-free survival of prostate cancer patients treated with salvage lymph node dissection via PSMA-radioguided surgery

Urologist – L. Budäus,Hamburg (DE)

O04       A MULTI-centre feasibility study to assess the use of 99m Tc-sestaMIBI SPECT/CT in the diagnosis of kidney tumours (MULTI-MIBI study)

Urologist – H. Warren,London (GB)

P010     Pre-magnetic resonance imaging (MRI) prostate-specific antigen density (PSAD) risk-stratification to avoid MRIs, biopsies and detection of low-risk prostate cancer: Results of the MR-PROPER study

A.M.A. Prinsen,Amsterdam (NL)

O06       The diagnostic value of fibroblast activation protein inhibitor positron emission tomography/computed tomography in genitourinary malignancies – a systematic review

Urologist – M.J. Hagens,Amsterdam (NL)